0001104659-24-007471.txt : 20240129 0001104659-24-007471.hdr.sgml : 20240129 20240129081208 ACCESSION NUMBER: 0001104659-24-007471 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240125 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Material Impairments ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240129 DATE AS OF CHANGE: 20240129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOOKIPA Pharma Inc. CENTRAL INDEX KEY: 0001760542 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 815395687 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38869 FILM NUMBER: 24570251 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET STREET 2: 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 0114318906360 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET STREET 2: 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 8-K 1 tm244291d1_8k.htm FORM 8-K
false 0001760542 0001760542 2024-01-25 2024-01-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 25, 2024

 

HOOKIPA PHARMA INC.

(Exact name of  Registrant as Specified in Its Charter)

 

Delaware   001-38869   81-5395687

(State or Other Jurisdiction of
Incorporation)

  

(Commission
File Number)

  

(IRS Employer
Identification No.)

 

350 Fifth Avenue, 72nd Floor,

Suite 7240

  
New York, New York   10118
(Address of principal executive offices)   (zip code)

 

Registrant’s telephone number, including area code: +43 1 890 63 60

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of exchange on which registered
Common stock, $0.0001 HOOK The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 

 

 

 

Item 1.02    Termination of a Material Definitive Agreement.

 

On January 25, 2024, HOOKIPA Pharma Inc. (“HOOKIPA”) received written notice (the “Notice”) from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively referred to as “Roche”) of their decision to terminate the Research Collaboration and License Agreement (the “Collaboration Agreement”) among Roche and Hookipa Biotech GmbH (“HOOKIPA GmbH,” and together with HOOKIPA, the “Company”), a wholly-owned subsidiary of HOOKIPA, dated October 18, 2022. Roche’s decision to terminate the Collaboration Agreement was made according to Roche’s right to terminate without cause, acknowledging that, to date, HOOKIPA met all go-forward criteria under the Collaboration Agreement.

 

The Collaboration Agreement was entered into to (i) grant Roche an exclusive license to research, develop, manufacture and commercialize the Company's pre-clinical HB-700 cancer program, an arenaviral immunotherapeutic for KRAS-mutated cancers, and (ii) grant Roche an option right to exclusively license for research, development manufacturing and commercialization, a second, novel arenaviral immunotherapeutic program targeting undisclosed cancer antigens.

 

Pursuant to the terms of the Collaboration Agreement and the Notice, the Collaboration Agreement will be terminated on April 25, 2024. The Company remains eligible for a final milestone payment associated with an IND submission. Effective April 25, 2024, the Company will regain full control of the associated intellectual property portfolio and will have full collaboration and licensing rights for the HB-700 program. After the termination of the Collaboration Agreement, and except as disclosed above, there is no other material relationship between the Company and Roche.

 

Item 2.02    Results of Operations and Financial Condition.

 

On January 29, 2024, HOOKIPA issued a press release which contained information regarding its preliminary, unaudited estimate of cash and cash equivalents and restricted cash of approximately $117.5 million as of December 31, 2023. This information is preliminary and unaudited. Accordingly, undue reliance should not be placed on such preliminary numbers. The Company expects to report its audited cash, cash equivalents and marketable securities, as well as other information necessary for a complete understanding of its financial position, in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

 

The information in this Item 2.02 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if such subsequent filing specifically references the information furnished pursuant to Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K.

 

Item 2.05    Costs Associated with Exit or Disposal Activities.

 

On January 29, 2024, HOOKIPA announced its decision to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease and to pause development activities related to HB-300 and most of its preclinical research activities. In connection with this strategic refocus, on January 22, 2024, HOOKIPA’s board of directors approved a plan to reduce the Company’s workforce by 55 full-time employees, or approximately 30% of the Company’s then-current employee base and to rebalance the Company’s cost structure in alignment with the new prioritization of R&D programs (together, the “Reduction Plan”), and the Company notified affected employees on January 29, 2024. HOOKIPA expects to implement and substantially complete the Reduction Plan during the first quarter of 2024. In connection with the Reduction Plan, the affected employees will be provided severance benefits, including cash severance payments. Each affected employee’s eligibility for these severance benefits is contingent upon such employee’s entering into an effective separation agreement, which includes a general release of claims against the Company. The workforce reduction is expected to result in approximately $1.5 million in severance, restructuring and related costs. HOOKIPA expects a non-cash impairment of “assets under construction” between $10 million and $13 million from the discontinuation of the GMP facility project as part of the Reduction Plan. The Company expects to recognize deferred upfront and milestone payments under the Collaboration Agreement of approximately $20 million in connection with the termination by Roche.

 

 

 

 

The estimated charges that the Company expects to incur in connection with this Reduction Plan are subject to a number of assumptions, and actual results may differ materially from these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Reduction Plan.

 

Item 2.06    Material Impairments.

 

To the extent applicable, the information contained in Item 2.05 above is incorporated into this Item 2.06 by reference.

 

Item 7.01    Regulation FD Disclosure.

 

On January 29, 2024, the Company issued a press release announcing updates on the Company’s business priorities and oncology partnership programs. A copy of the press release is furnished hereto as Exhibit 99.1.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Forward Looking Statements

 

This Current Report on Form 8-K and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding HOOKIPA’s expectation about any or all of the following: (i) the timing and consequences regarding the termination of the Collaboration Agreement, (ii) the extent, timing and plan of, and the costs and estimated cash expenditures from, the Reduction Plan, and (iii) expected cash and cash equivalents as of December 31, 2023. Forward-looking statements can be identified by terms such as “will,” “intent,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. HOOKIPA has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Although HOOKIPA believes that such statements are based on reasonable assumptions, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond HOOKIPA’s control, you should not rely on these forward-looking statements as predictions of future events. These risks and uncertainties include, among others: outcomes of HOOKIPA’s planned clinical trials and studies may not be favorable; that one or more of HOOKIPA’s product candidate programs will not proceed as planned for technical, scientific or commercial reasons; availability and timing of results from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical trials or to market a products; uncertainties regarding intellection property protection; and those risk and uncertainties described under the heading “Risk Factors” in HOOKIPA’s Form 10-Q for the quarter ended September 30, 2023 filed with the U.S. Securities and Exchange Commission, and in any other subsequent filings made by HOOKIPA with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. HOOKIPA disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this Current Report on Form 8-K, other than to the extent required by law.

 

Item 9.01. Exhibits.

 

(d) Exhibits  

 

99.1   Press Release issued by HOOKIPA Pharma Inc. on January 29, 2024, furnished herewith.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HOOKIPA Pharma Inc.
   
Date: January 29, 2024 By: /s/ Joern Aldag
    Joern Aldag
    Chief Executive Officer
    (Principal Executive Officer)

 

 

 

 EX-99.1 2 tm244291d1_ex99-1.htm EXHIBIT 99-1

Exhibit 99.1

 

 

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

 

·HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease

 

·HOOKIPA will regain global development rights to HB-700 program for KRAS-mutated cancers from Roche; HOOKIPA remains eligible for milestone payment associated with submission of Investigational New Drug application

 

·HOOKIPA will implement cost saving initiatives, including a reduction of workforce by approximately 30 percent

 

·HOOKIPA maintains a strong cash position of $117.5 million as of December 31, 20231

 

NEW YORK and VIENNA, January 29, 2024 – HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company will focus its resources in two strategic areas: (1) prioritize the clinical development of a randomized trial for its HB-200 program in human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) and (2) its two Gilead-partnered infectious disease cure programs for hepatitis B and human immunodeficiency virus.

 

In the first-line setting HB-200, in combination with pembrolizumab, has demonstrated best-in-class antigen specific T cell activation and has doubled the historic objective response rates of standard of care treatment alone. The totality of the HB-200 data presents a clear opportunity for HOOKIPA to advance this program in a randomized trial starting in mid-2024.

 

“HOOKIPA has a tremendous opportunity to transform treatment of multiple disease areas using an entirely new class of medicines,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “As we move forward with our randomized trial for HB-200 in combination with pembrolizumab, we have made an important decision to focus our resources and pursue this opportunity in earnest. We will focus on clinical delivery and execution so that we can help address a significant unmet need for patients with advanced HPV16+ head and neck cancer.”

 

The Company also announced that it has received notification from Roche of their decision to terminate the collaboration and licensing agreement for HOOKIPA’s HB-700 program in KRAS mutated cancers. To date, HOOKIPA has met all go-forward criteria under the agreement and remains eligible for a final milestone payment associated with IND submission. Effective April 25, 2024, HOOKIPA will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for this program. As part of its strategic refocus, HOOKIPA will pause development activities related to HB-300 and most of its preclinical research activities.

 

 

 

 

HOOKIPA will reduce its workforce by approximately 30 percent and rebalance its cost structure in alignment with the new prioritization of the Company’s programs. HOOKIPA maintains a strong cash position of $117.5 million1 as of December 31, 2023, and believes that the planned reductions will help to conserve resources and better align its organization in direct support of late stage clinical development efforts.

 

Pipeline Update and Upcoming Catalysts

 

The strategic priorities for HOOKIPA are to advance its clinical programs including HB-200 and its two Gilead-partnered infectious disease programs. The Company is planning to submit an IND for HB-700 in the first quarter of 2024 and will begin searching for a collaboration partner. At this time, the company will not pursue further preclinical programs into development and pause further development of its HB-300 to conserve capital and ensure pipeline success and operational efficiency.

 

Program Indication Upcoming Catalysts
Oncology Programs
HB-200 HPV16+ HNSCC

· Additional first-line data for HB-200 in combination with pembrolizumab (1H 2024)

· Initiation of randomized trial (mid-2024)

HB-700 KRAS

· IND submission (1Q 2024)

· Publication of preclinical research (1H 2024)

· Search for new collaboration partner

 
Infectious Disease Programs: Gilead-Partnered
HB-400 HBV

· Gilead-led: Phase 1b actively enrolling

· Next milestone: Phase 2 initiation (Timing TBD)

HB-500 HIV

· Initiation of Phase 1 trial

· First patient dosed, milestone payment (1H 2024)

 
Paused Programs
HB-300 Prostate Cancer · Paused and utilize capital to support HB-200 development
Preclinical Multiple targets

 

 

1 Cash position as of December 31, 2023, is unaudited

 

About HOOKIPA

 

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other unnamed indications. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

 

Find out more about HOOKIPA online at www.hookipapharma.com.

 

 

 

 

Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements by HOOKIPA regarding: timing and consequences regarding the termination of the Roche Collaboration Agreement, the extent, timing and plan of and the costs and estimated cash expenditures from, the reduction of workforce, and expected cash and cash equivalents as of December 31, 2023. Forward-looking statements can be identified by terms such as “will,” “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from public health crises, the impact of public health crises on the enrollment of patients and timing of clinical results, and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s annual report on Form 10-K for the period ended December 31, 2022, quarterly report on Form 10-Q for the quarter ended September 30, 2023 and other important factors in HOOKIPA’s subsequent filings with the Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov and HOOKIPA’s website at http://hookipapharma.com/. In addition, any forward-looking statements represent HOOKIPA’s views only as of today and should not be relied upon as representing its views as of any subsequent date. HOOKIPA explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

 

Availability of Other Information About HOOKIPA

 

Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.

 

For further information, please contact:

 

Investors and Media

Michael Kaiser

michael.kaiser@hookipapharma.com

+ 1 (917) 984 7537

 

 

 

 EX-101.SCH 3 hook-20240125.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hook-20240125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 hook-20240125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm244291d1_ex99-1img001.jpg GRAPHIC begin 644 tm244291d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Jan. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 25, 2024
Entity File Number 001-38869
Entity Registrant Name HOOKIPA PHARMA INC.
Entity Central Index Key 0001760542
Entity Tax Identification Number 81-5395687
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 350 Fifth Avenue, 72nd Floor,
Entity Address, Address Line Two Suite 7240
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10118
City Area Code +43
Local Phone Number 1 890 63 60
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.0001
Trading Symbol HOOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://hookipapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hook-20240125.xsd hook-20240125_lab.xml hook-20240125_pre.xml tm244291d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm244291d1_8k.htm": { "nsprefix": "hook", "nsuri": "http://hookipapharma.com/20240125", "dts": { "schema": { "local": [ "hook-20240125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hook-20240125_lab.xml" ] }, "presentationLink": { "local": [ "hook-20240125_pre.xml" ] }, "inline": { "local": [ "tm244291d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://hookipapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm244291d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm244291d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-007471-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-007471-xbrl.zip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end XML 17 tm244291d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001760542 2024-01-25 2024-01-25 iso4217:USD shares iso4217:USD shares false 0001760542 8-K 2024-01-25 HOOKIPA PHARMA INC. DE 001-38869 81-5395687 350 Fifth Avenue, 72nd Floor, Suite 7240 New York NY 10118 +43 1 890 63 60 false false false false Common stock, $0.0001 HOOK NASDAQ true true